Sarasota, FL -- (SBWIRE) -- 11/21/2018 -- Global monoclonal antibody therapeutics market is displaying a highly competitive business landscape, finds a new research report by Zion Market Research (ZMR). F. Hoffmann-La Roche Limited, Pfizer Incorporation, Bayer AG, GlaxoSmithKline Plc, and Novartis AG are some of the key vendors of monoclonal antibody therapeutics across the world. These players are focusing aggressively on innovation, as well as on including advanced technologies in their existing products. Over the coming years, they are also expected to take up partnerships and mergers and acquisitions as their key strategy for business development, states the monoclonal antibody therapeutics market study.

Citing an instance, in August 2018, a group of scientists published a study titled "Systematic analysis of monoclonal antibodies against Ebola virus GP defines features that contribute to protection" in Cell Journal. Reportedly, the study unleashes that therapeutic antibodies have the ability to halt the proliferating growth of Ebola virus.

DOWNLOAD FREE PDF BROCHURE @ https://bit.ly/2OUsjxt

Rise In the Cancer Cases Across The Globe To Boost Market Revenue

"Monoclonal antibody therapeutics market is anticipated to get traction over the coming years, owing to its myriad applications in treatment of cancer, autoimmune ailments, hematological disorders, and infections," says the author of this study. Apart from this, rising incidences of cancer along with humungous investments in R&D activities to develop new antibodies witnessed in Europe and U.S. is anticipated to uplift the growth graph of monoclonal antibody therapeutics market over the forthcoming years. In addition to this, speedy approval as well as commercialization of these antibodies is expected to contribute substantially towards monoclonal antibody therapeutics market revenue in the years ahead.

Escalating production of biosimilars, however, is anticipated to hamper the growth of monoclonal antibody therapeutics market in the near future. In addition to this, patent expiry of large number of monoclonal antibodies along with the complex & costly procedure involved in production of these antibodies is forecast to obstruct the monoclonal antibody therapeutics market scope in the coming years.

Wide Acceptance Of Monoclonal Antibodies To Push North American Dominance

Regionally, North America has been leading the worldwide monoclonal antibody therapeutics market and is anticipated to continue on the dominant position in the years to come, states the monoclonal antibody therapeutics market study. Rapid acceptance of monoclonal antibodies in the region is the main factor behind the dominance of the North America monoclonal antibody therapeutics market. The high number of market players being headquartered in North America is another significant factor that is supporting the progression of this regional monoclonal antibody therapeutics market.

Get Free Sample Research Report @ https://bit.ly/2qZ1sqo

The global monoclonal antibody therapeutics market is segmented as follows:

By Application

Cancer
Autoimmune Diseases
Infection
Hematological Diseases
Others
By Source

Human
Humanized
Chimeric
Others
By End-User

Hospitals
Private Clinics
Research Institute
By Region

North America
The U.S.
Europe
UK
France
Germany
Asia Pacific
China
Japan
India
Latin America
Brazil
The Middle East and Africa